NovaBay Pharmaceuticals Inc.

1.08-0.0600-5.26%Vol 2.55M1Y Perf -32.61%
Jul 2nd, 2020 16:00 DELAYED
BID1.07 ASK1.08
Open1.09 Previous Close1.14
Pre-Market1.12 After-Market1.08
 -0.02 -1.75%  - -%
Target Price
1.50 
Analyst Rating
Strong Buy 1.00
Potential %
38.89 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     26.01
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     21.31
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap31.12M 
Earnings Rating
Buy
Price Range Ratio 52W %
52.17 
Earnings Date
5th Aug 2020

Today's Price Range

1.051.11

52W Range

0.24001.85

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-1.82%
1 Month
31.05%
3 Months
33.33%
6 Months
71.43%
1 Year
-32.61%
3 Years
-71.20%
5 Years
-93.35%
10 Years
-97.84%

TickerPriceChg.Chg.%
NBY1.08-0.0600-5.26
AAPL368.514.40001.21
GOOG1 464.7026.66001.85
MSFT206.261.56000.76
XOM44.080.37000.85
WFC25.340.25001.00
JNJ140.970.59000.42
FB233.42-4.1300-1.74
GE6.820.08001.19
JPM92.66-0.6000-0.64
Financial StrengthValueIndustryS&P 500US Markets
1.20
1.40
0.34
4.16
-
Leverage Ratio 8.70
ProfitabilityValueIndustryS&P 500US Markets
71.70
-98.10
-97.20
-156.50
-99.05
RevenueValueIndustryS&P 500US Markets
7.00M
0.21
-23.56
28.85
Earnings HistoryEstimateReportedSurprise %
Q01 2020--0.06-
Q04 2019--0.13-
Q03 2019--0.02-
Q02 2019--0.14-
Q01 2019--0.24-
Q04 2018-0.14-0.0935.71
Q03 2018-0.09-0.11-22.22
Q02 2018-0.12-0.15-25.00
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.18-20.00Negative
6/2019 QR-0.0650.00Positive
12/2020 FY-0.22--
12/2021 FY-0.09--
Next Report Date5th Aug 2020
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume2.55M
Shares Outstanding28.81M
Trades Count5.56K
Dollar Volume2.66M
Avg. Volume3.23M
Avg. Weekly Volume6.10M
Avg. Monthly Volume5.67M
Avg. Quarterly Volume4.28M

NovaBay Pharmaceuticals Inc. (AMEX: NBY) stock closed at 1.08 per share at the end of the most recent trading day (a -5.26% change compared to the prior day closing price) with a volume of 4.16M shares and market capitalization of 31.12M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 33 people. NovaBay Pharmaceuticals Inc. CEO is Justin M. Hall.

The one-year performance of NovaBay Pharmaceuticals Inc. stock is -32.61%, while year-to-date (YTD) performance is 68.75%. NBY stock has a five-year performance of -93.35%. Its 52-week range is between 0.24 and 1.85, which gives NBY stock a 52-week price range ratio of 52.17%

NovaBay Pharmaceuticals Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 26.71, a price-to-sale (PS) ratio of 5.53, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -82.10%, a ROC of -182.70% and a ROE of -2 020.51%. The company’s profit margin is -99.05%, its EBITDA margin is -97.20%, and its revenue ttm is $7.00 Million , which makes it $0.21 revenue per share.

Of the last four earnings reports from NovaBay Pharmaceuticals Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. NovaBay Pharmaceuticals Inc.’s next earnings report date is 05th Aug 2020.

The consensus rating of Wall Street analysts for NovaBay Pharmaceuticals Inc. is Strong Buy (1), with a target price of $1.5, which is +38.89% compared to the current price. The earnings rating for NovaBay Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

NovaBay Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

NovaBay Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 50.24, ATR14 : 0.12, CCI20 : 58.76, Chaikin Money Flow : 0.07, MACD : 0.06, Money Flow Index : 73.75, ROC : 24.48, RSI : 55.96, STOCH (14,3) : 51.92, STOCH RSI : 0.00, UO : 48.79, Williams %R : -48.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of NovaBay Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company. The company develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eyecare market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox). NovaBay develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets.

CEO: Justin M. Hall

Teplephone: +1 510 899-8800

Address: 2000 Powell Street, Emeryville 94608, CA, USA

Number of employees: 33

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

60%40%

Bearish Bullish

53%47%

News

Stocktwits